anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined by a method which determines the initial hydrolysis rate of the substrate by using MALDI-TOF/MS.  Alternatively, the subsite specificity of mepapsin can be determined by probing a library of inhibitors with memapsin 2 and subsequently detecting the bound memapsin 2 with an antibody raised to memapsin 2 and an alkaline phosphatase conjugated secondary antibody. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2.  Processes for the synthesis of substrate analogues including isoteres at the sites of the critical amino acid residues were developed and the more than seventy substrate analogues were synthetized, among which MMI-005, MMI-012, MMI-017, MMI-018, MMI-025, MMI-026, MMI-037, MMI-039, MMI-040, MMI-066, MMI-070, and MMI-071 have inhibition constants in the range of 1.4-61.4 x 109 M  against recombinant pro-memapsin 2. These inhibitors are useful in diagnostics and for the treatment and/or prevention of Alzheimer's disease.
A tasteless crystalline neutral tetracycline of good colour is prepared by adjusting the pH of an aqueous solution or slurry of crude tetracycline to a pH of not greater than 2.0, preferably 0.5 to 2.0 and especially 1.0, filtering, adding one or more sulphites selected from the alkali metal sulphites and ammonium sulphite, and adjusting the pH to between 2.0 and 3.0 in order to precipitate the tetracycline.  0.9 to 15 and preferably 5 to 10% of sulphite (based on total tetracycline content) is used.  The tetracycline may be produced by fermentation or by the catalytic dechlorination of chlortetracycline.  Acids such as hydrochloric and sulphuric and alkalies such as sodium hydroxide are used for adjustment of pH.  The tetracycline is used orally (see Group VI). Specifications 775,115 and 787,056 are referred to.ALSO:A tasteless crystalline tetracycline of good colour (see Group IV (b)) is used in oral pharmaceutical preparations such as syrups, oral suspensions and liquid pediatric drops. Specifications 775,115 and 787,056, [Group IV (b)], are referred to.
Transcranial direct current stimulation (tDCS) is a safe, non-invasive neuromodulation technique that shows promise as an intervention technique. The primary aim of this study is to assess the magnitude of tDCS-induced cognitive and functional change in patients with mild traumatic brain injury (TBI). In this double-blind, sham-controlled, pilot study, 24 veterans with mild TBI will be randomized to tDCS or sham conditions. Stimulation will be administered with a StarStim neurostimulator at 2 milliamps (mA) for 20 minutes. The anodal electrode will be placed over the left dorsal lateral prefrontal cortex. Twenty-four sessions of stimulation will be administered concurrent with 20 minutes of working memory training. Participants will continue with an additional 40 minutes of working memory training post-stimulation. Participant experience with neuromodulation will be assessed with a self-report questionnaire that lists common reactions to tDCS. Participant perception of the value of neuromodulation procedures will be assessed at weeks 4 and 8. A second aim is to identify biomarkers of treatment response. Resting state electroencephalogram (EEG) will be collected at three time points: prior to the first tDCS training session, immediately after the first training session, and post-intervention. This study will provide preliminary evidence of the efficacy of providing tDCS as an intervention to enhance cognitive and functional outcomes for individuals with mild traumatic brain injury. Furthermore, the results of this study will also increase the understanding of the mechanisms by which tDCS enhances cognitive performance. This knowledge has the potential to provide insight into the underlying therapeutic process as well as to guide development of the next generation of interventions. In addition, acceptability of the intervention will be monitored to identify potential barriers to administering tDCS in clinical practice.
FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to an ointment with an antifungal effect. Invention proposes nystatin ointment on polymer base comprising propylene glycol and polyethylene oxide-1500 as accessory substances. An ointment does not contain drug particles since it presents the ointment-solution system. EFFECT: enhanced effectiveness of ointment as compared with other agents. 2 tbl
For this clinical investigation, the clinical data for 325 subjects were used to demonstrate the non-inferiority of iAST® application in comparison with physician prescription. In any case, the data retrospectively analyzed for these 325 subjects were simulated using the iAST® application, in such a way that the same subjects were considered case and control at the same time.
Glaucoma is a chronic disease of the eye which results in gradual loss of nerve fibres, resulting in visual loss. The mainstay of treatment is reduction of intraocular pressure (IOP), which has been shown to preserve vision, and glaucoma surgery aims to achieve this. One type of surgery involves insertion of a glaucoma drainage device (GDD). Following surgery steroid eye drops are commonly used in order to reduce the inflammation that occurs as a result of the surgery. However, a common side effect of steroid eye drops is a rise in eye pressure. Non-steroidal anti-inflammatory drugs (NSAID) eye drops do not have this side effect and are used as an alternative to steroids following other types of eye surgery. Use of NSAID drops following GDD surgery may result in improved eye pressure. This study aims to evaluate the eye pressure response to NSAID eye drops following GDD surgery.
Group 2. Usual care. Patients are encouraged to remain physically active, although they do not participate in a regular structured exercise training program.
MAXALT should not be given to patients with ischemic or vasospastic coronary artery disease. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of MAXALT. Some of these reactions occurred in patients without known coronary artery disease (CAD). 5-HT1 agonists, including MAXALT may cause coronary artery vasospasm (Prinzmetal's Angina), even in patients without a history of CAD.

Triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) should have a cardiovascular evaluation prior to receiving MAXALT. If there is evidence of CAD or coronary artery vasospasm, MAXALT should not be administered [see Contraindications (4)]. For patients who have a negative cardiovascular evaluation, consideration should be given to administration of the first MAXALT dose in a medically-supervised setting and performing an electrocardiogram (ECG) immediately following MAXALT administration. Periodic cardiovascular evaluation should be considered in intermittent long-term users of MAXALT who have cardiovascular risk factors.
The invention relates to powder for burns and scalds. The medicament is prepared by preparing, fire attack and refining a composition taking 10 grams of toilet paper, 89.5 grams of cane sugar and 0.5 gram of bulbus fritilariae as raw materials, and the percentages of the raw materials are: 10 percent of bamboo-made toilet paper, 89.5 percent of f cane sugar and 0.5 percent of bulbus fritilariae. Fritillaria is crushed to be fine powder mixed well with sugar; the toilet paper is put on a plank flat; 25 grams of mixed sugar raw material is scattered on the edge of the toilet paper in a straight line in order to rub and roll the toilet paper to be a strip; 20 strips are put in an iron pot as a bundle and burnt; the obtained product is crushed to be grains like flour in a pulverizer and the iron pot after fire naturally goes out; and pure rapeseed oil and medicinal powder are mixed in a ratio of 7:3, namely 70 percent of medicinal powder and 30 percent of oil. In order to save cost, oil medicinal powder is diluted and stirred to be paste smeared on a wound according to the size of the wound once to twice a day to keep the wound with the medicament, and after diluted medicinal solvent is smeared, the wound needs no dressing change or dressing. The medicament has the effects of relieving pain, moistening skin, promoting tissue regeneration, preventing suppuration, eliminating swellings and producing no toxic-side effects. The wound of which 80 percent of the surface is 1 to 5 millimeters in depth can be treated to heal within 15 days. A slight wound of which 40 percent of the surface is 1 to 3 millimeters in depth can be treated to heal within 8 days. Original skin color can be restored within 1 to 3 months without leaving any scars or color. The medicament has the advantages of excellent effect, low cost and capability of saving 50 percent of medical expense for patients.
FIELD: organic chemistry, chemical technology, medicine, pharmacy. SUBSTANCE: invention relates to novel derivatives of azolidinedione of the formula (1)   where one of X, Y and Z means c=O or C=S and one of remaining X, Y and Z means group C= and others mean C= C; R 1 , R 2 , R 3  are substituted either by X, Y and Z or by nitrogen atom and they can be similar or different and mean hydrogen, halogen atom, hydroxy-group, nitro-group and others; group -(CH 2 ) n -O can be linked through nitrogen atom or X, Y, Z; n = 1-4; Ar means phenylene or naphthylene; R 4  means hydrogen atom or forms a bond with the group A; A means nitrogen atom or CR 5  where R 5  means hydrogen, halogen atom or forms a bond with R 4 ; B means O or S atom when A means CR 5 ; B means O atom when A means N atom; its tautomeric forms, stereoisomers, polymorphic forms, pharmaceutically acceptable salts and solvates. Invention relates also to method of synthesis of compound of the formula (1) by interaction of compound of the formula (VIII)   with compound of the formula (XII)   and so on. Invention relates also to pharmaceutical composition eliciting antidiabetic activity and containing compound of the formula (1) and pharmaceutically acceptable carrier, vehicle, filling agent or solvate. Invention relates also to method of prophylaxis or treatment of diseases where insulin non-susceptibility confers the base of pathophysiological mechanism involving administration of compound of the formula (1) in patient needing with its. Invention relates also to method of reduction of blood glucose, plasma triglycerides or free fatty acids involving administration of compound of the formula (1) in patient needing with its. Invention relates to intermediate compound of the formula (III)   where G means -CHO, -NH 2 , - CH=NOH and so on; J means hydroxy-group, halogen atom; R means hydrogen atom, lower alkyl; one of X, Y and Z means C=O or C=S and one of remaining X, Y and Z means group C= and others mean group C=C; R 1 , R 2 , R 3  are substituted by either X, Y and Z or by nitrogen atom and they can be similar or different and mean hydrogen, halogen atom, hydroxy-group, nitro-group and so on; or any two of R 1 , R 2 , R 3  in common with adjacent atoms to which they are bound can form substituted or unsubstituted 4-7- membered cycle with one or more double bonds and so on; group (CH 2 ) n -O- can be linked through nitrogen atom or X, Y, Z; n = 1-4; Ar means phenylene or naphthylene; R 4  means hydrogen atom or forms a bond with group A; A means nitrogen atom or CR 5  where R 5  means hydrogen, nitrogen atom or forms a bond with R 4 ; B means O or S atom when A means CR 5 ; B means O atom when A means N atom. Invention provides synthesis of novel derivatives of azolidinedione. EFFECT: improved method of synthesis, valuable medicinal properties of compounds. 24 cl, 3 tbl, 43 ex
The invention provides traditional Chinese medicine for treatment of multisystemic wasting syndrome of piglets. The traditional Chinese medicine comprises the following components by weight: 1-210 parts of elecampane, 1-210 parts of fructus amomi, 1-300 parts of rhizoma atractylodis macrocephalae, 1-300 parts of pericarpium citri reticulatae, 1-300 parts of poria cocos, 1-300 parts of prepared pinellia ternate, 1-210 parts of vinegar-containing rhizoma cyperi, 1-210 parts of fried immature bitter orange, 1-210 parts of peeled round cardamom, 1-210 parts of ginger-containing cortex magnoliae officinalis, 1-210 parts of pogostemon cablin and 1-90 parts of liquorice. In the scheme, the rhizoma atractylodis macrocephalae has the effects of tonifying qi and the spleen, removing dampness and alleviating water retention and is used as a monarch drug; the fructus amomi, round cardamom and pogostemon cablin have the effects of dissipating dampness, promoting the circulation of qi, neutralizing and controlling nausea and vomiting; the pericarpium citri reticulatae and cortex magnoliae officinalis have the effects of promoting the circulation of qi, neutralizing, dissipating dampness and eliminating stasis; and the elecampane and rhizoma cyperi have the effects of regulating vital energy, dispelling melancholy, harmonizing the stomach and removing pains and are used as ministerial drugs. The poria cocos has the effects of tonifying the spleen and promoting diuresis; the immature bitter orange has the effects of relieving stagnant qi, removing food retention and eliminating stagnation; the pinellia ternata has the effects of calming the adverse-rising energy, controlling nausea and vomiting and eliminating stagnation; and the poria cocos, immature bitter orange and pinellia ternata are used as adjuvant drugs. The liquorice is used for coordinating the nature of the medicine and is used as a conductant drug. By adopting the formula, the effects of tonifying the spleen, dissipating dampness, promoting the circulation of qi and neutralizing can be achieved, good curative effects can be achieved for the multisystemic wasting syndrome of weaned piglets, the curing rate is high, and piglets can grow well after being cured.
PURPOSE: Thyroid cancer generally has a good prognosis, and thyroidectomy is the main treatment given to thyroid cancer patients. Almost every cancer patient experiences varying degrees of distress, which can reduce their quality of life. This study aims to explore the level of distress and its relationship with illness perception and coping style among Chinese thyroid cancer patients after thyroidectomy and to identify the influencing factors on distress.
METHODS: A cross-sectional study with convenience sampling method was conducted. Totally 184 thyroid cancer patients after thyroidectomy were recruited in a tertiary hospital in Southern China with the response rate being 94.4% . The participants were investigated by a self-designed demographic and disease-related questionnaire, the Distress Management, the Brief Illness Perception Questionnaire, and the Medical Coping Modes Questionnaire. Descriptive statistics, univariate analysis, and multivariate linear regression were applied for data analysis.
RESULTS: In total, 99 (53.8%) thyroid cancer patients after thyroidectomy scored 4 or higher on the DT. Illness perception, emotional problem, body image loss by surgical scars, and acceptance-resignation were the influencing factors of distress and could explain 67.6% of the variance of distress among thyroid cancer patients after thyroidectomy.
CONCLUSIONS: Healthcare professionals should not ignore the distress among thyroid cancer patients after thyroidectomy and should take effective measures to alleviate the distress of thyroid cancer patients after thyroidectomy by enhancing their accurate and positive illness perceptions, decreasing their emotional problems, alleviating their body image loss by surgical scars, and avoiding acceptance-resignation coping style.
As part of standard of care, patients are routinely asked about any symptoms they might be experiencing. This study seeks to quantify these symptoms for research purposes. Participants will be identified through those who attend the pediatric pulmonary hypertension clinic at LPCH. Only children who are currently on one of seven PH medications (Bosentan, Epoprostenol, Letairis, Sildenafil, Tadalafil, Treprostinil, Ventaris) will be approached. Patients who consent to be in the study will answer a brief series of questions pertaining to the presence and duration of their symptoms. These will be correlated to a list of side effects taken from Lexicomp (a medication database).
The invention relates to a water-soluble barm Beta-dextran and a preparation method thereof. In the water-soluble barm Beta-dextran chain, Beta-1, 3-dextran is taken as a main chain, Beta-1, 6-dextran is taken as a branched chain, the molecular weight is 0.08 to 0.2 million Daltun. The preparation method of the water-soluble barm Beta-dextran includes the following steps of: water extraction, alkali extraction and impurity processing. The preparation technique of the invention is simple; the technique parameters are easy to be operated and controlled; both the yield and the purity of the product water-soluble barm Beta-dextran are higher. The obtained water-soluble barm Beta-dextran has remarkable immune activation effect and especially can improve the phagocytic function and the antibodyformation capacity of a macrophage to a large extent, thereby improving the body immunity and resistance. The water-soluble barm Beta-dextran can be widely applied in the fields such as food, dairy food and drinks, etc.
Vaginal prolapse (a feeling of bulge in the vagina) may cause some distressing symptoms such as loss of control of the bowel or bladder, and may also cause problems with women's sex life. There are a number of different surgical procedures which are used to repair prolapse. Sometimes a mesh is placed in the pelvis to support the weakened tissues. There is a lot of research going on to find the most suitable type of mesh to repair vaginal prolapse. The GYNECARE PROLIFT + M\* Pelvic Floor Repair system is similar to a mesh already used for this procedure called ULTRAPRO\*, but is lighter in weight. Currently, ULTRAPRO\* is only approved for use in hernia repair and is not licensed for gynecological procedures. This study will be the first clinical investigation of this mesh in vaginal prolapse.
A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of topiramate and pioglitazone when administered alone and concomitantly. A 15% decrease in the AUCτ,SS of pioglitazone with no alteration in Cmax,ss was observed. This finding was not statistically significant. In addition, a 13% and 16% decrease in Cmax,ss and AUCτ,SS respectively, of the active hydroxy-metabolite was noted as well as a 60% decrease in Cmax,ss and AUCτ,SS of the active keto-metabolite. The clinical significance of these findings is not known. When topiramate is added to pioglitazone therapy or pioglitazone is added to topiramate therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state.
Described herein is the synthesis of adhesive complex coacervates and their use thereof. The adhesive complex coacervates are produced by reacting (a) at least one poly anion comprising a plurality of activated ester groups, and (b) at least one polycation comprising a plurality of nucleophilic groups, wherein the nucleophilic groups react with the activated ester groups to produce a new oovalent bond between the polycation and the polyanion. The adhesive complex coacervates described herein have low interfacial tension with water and wettable substrates. When applied to a wet substrate they spread over the interface rather than beading up. The adhesive complex coacervates have numerous biological applications as bioadhesives and drug delivery devices. In particular, the adhesive complex coacervates described herein are particularly useful in wet or underwater applications and situations where water is present such as, for example, physiological conditions.
The SuperDOT-C study will evaluate a new pathway of care for patients on OST who are already receiving OST therapy on a daily basis from a pharmacist. Newer therapies for HCV have recently become much simpler to initiate and supervise with much improved effectiveness and as described below it is now proposed to extend the role of community pharmacists into initiating HCV therapy alongside the existing OST The SuperDOT-C study will utilise this existing environment and relationship to smooth the pathway into HCV therapy with co-administration of OST alongside the anti-HCV therapy under the supervision of the pharmacist compared with the established pathway of referral to another site and treatment with a nurse led ant-HCV treatment program. This new pathway may have positive effects on the movement towards HCV cure at multiple levels. The planned pathway is different to current care at each point, from testing and diagnosis through adherence to cure. In the planned pathway, the patient interacts with the pharmacist on a daily basis, as compared to intermittent interaction with a secondary care team member. The result being that the patient has a shorter care pathway, with less travelling and better access to anti-HCV treatment. The daily interaction with the pharmacy provides opportunities to assess and support the patient, provide sound advice and care, with the added benefit of being able to directly observe treatment, (DOT), thus potentially improving adherence.
Evening chronotype individuals experience pain more often than morning chronotypes, but relationships with pain sensitivity have rarely been studied. We examined whether chronotype is associated with pressure pain sensitivity, with special reference to mental health disorders, insomnia, and chronic musculoskeletal (MSK) pain as potential moderating factors. The study sample consisted of members of the Northern Finland Birth Cohort 1966 aged 46. Pressure pain threshold and tolerance were measured via the standardized protocol, categorized as lowest quartile versus others. Chronotype (morning [M; the reference], intermediate [I], and evening [E]) was defined using the Short Morningness-Eveningness questionnaire. Sex-stratified binary logistic regression models were separately adjusted for education, body mass index, long-term diseases (fully adjusted model), and for mental health disorders, insomnia, and chronic MSK pain (a residual confounding analysis). Interaction terms (Chronotype × Mental health/insomnia/chronic MSK pain) were tested. The study had 2,132 males and 2,830 females. The E-type males had 1.5-fold odds of having a low pain threshold (fully adjusted odds ratio [OR] 1.45, 95% confidence interval 1.05-2.00) and pressure pain tolerance (fully adjusted OR 1.47, 1.07-2.02), in comparison to M-types. Having a mental health disorder intensified the association with low pain threshold fourfold (4.06, 1.56-10.6). Being an E-type female was also associated with a low pain threshold, but the association was statistically nonsignificant (fully adjusted OR 1.18, .90-1.53). No statistically significant interactions were found among females. These results emphasize the role of chronotype in pain sensitivity and add an understanding of pain experience in light of innate circadian types. PERSPECTIVE: Male evening chronotypes are more sensitive to pain than morning chronotypes. Diagnosed mental health disorders in particular indicate a low pain threshold for evening chronotype males.